Smart Trade Insights
  • Business
  • Economy
  • Investing
  • Politics
Top Posts
Troy Minerals Updates on Channel Sampling at Table...
McEwen to Acquire Canadian Gold in All-share Deal
Crypto Market Update: Corporate Bitcoin Treasuries Jump to...
AFDG via Butembo Acquisition Becomes First US Public...
Tactical Resources Provides Rare Earths Business Update in...
AF2 Capital Corp. Enters into Letter of Intent...
Strategic Entry into Australian Gas Infrastructure Sector
Don Durrett: Gold, Silver Miners to Rip Even...
Completes Two Pools Gold Acquisition
Convertible Note and Placement
  • Business
  • Economy
  • Investing
  • Politics

Smart Trade Insights

Business

FDA officially authorizes Zyn nicotine pouches for sale following health review

by admin January 18, 2025
January 18, 2025
FDA officially authorizes Zyn nicotine pouches for sale following health review

The U.S. Food and Drug Administration formally authorized Zyn nicotine pouches for sale after conducting an ‘extensive scientific review’ about their safety.

In a release Thursday, the agency said it had found that the popular pouches posed lower risk of cancer and other serious health conditions compared with cigarettes, as well as in relation to other smokeless tobacco products.

The agency also found that the pouches even had the potential to benefit cigarette smokers amid evidence that they can get them to quit.

‘The data show that these nicotine pouch products meet that bar by benefiting adults who use cigarettes and/or smokeless tobacco products and completely switch to these products,” Matthew Farrelly, director of the office of science in the FDA’s Center for Tobacco Products, said in a statement. 

Zyn use has exploded in recent years in the wake of a viral online meme trend, even prompting a shortage last year. Yet the product had been operating in a legal gray area while it underwent official FDA review about its health effects and uptake among young users.

To that latter point, the FDA found that, so far, Zyn use among youths appeared to be relatively low, though it was continuing to monitor the trend.

A spokesperson for Philip Morris International Inc., which owns the U.S. rights to Zyn, did not immediately respond to a request for comment.

Swedish Match, the developer of Zyn, said in a statement, “The FDA’s authorization of all ZYN nicotine pouches currently marketed by Swedish Match in the U.S. is an important step to protect the public health by providing better alternatives to cigarettes and other traditional tobacco products for adults 21+.”

The Campaign for Tobacco-Free Kids slammed the FDA’s decision in a separate statement.

‘The FDA today has set a dangerous precedent that puts the nation’s kids at risk by authorizing the sale of 20 Zyn nicotine pouch products with flavors that clearly appeal to kids, including chill, citrus, cool mint and peppermint,’ it said.

‘The FDA’s decision is deeply troubling given the extensive scientific evidence that flavored tobacco products appeal to kids and the fact that nicotine pouches were the only category of tobacco product that saw an increase in youth use last year. The FDA is sanctioning a flavored tobacco product that is already increasing in popularity with kids and repeating the mistakes it made with Juul that resulted in the youth e-cigarette epidemic.’

In the release, the FDA emphasized that its findings about Zyn did not mean the products are ultimately safe or “FDA approved.”

‘There is no safe tobacco product,’ the agency said. ‘Youth should not use tobacco products and adults who do not use tobacco products should not start.’

This post appeared first on NBC NEWS

previous post
Biden Admin Enacts Tougher Regulations for Chip and Connected Vehicle Sectors
next post
Vanguard fined more than $100 million by SEC over violations involving target date retirement funds

You may also like

JPMorgan marks 1,000th branch opening since 2018 expansion...

August 2, 2025

Possible work stoppage at Canada’s two largest railroads...

August 20, 2024

GM lays off 1,000 employees amid reorganization and...

November 17, 2024

FDA declares cucumber-linked Salmonella outbreak over after 155...

August 27, 2024

Digital health companies got pummeled by Wall Street...

December 26, 2024

Apple looking to make ‘premium’-priced folding iPhones starting...

June 21, 2025

Dick’s Sporting Goods stands by full-year guidance —...

May 29, 2025

Disney to combine its Hulu+ Live TV with...

January 7, 2025

Apple has survived Trump’s tariffs so far. It...

September 5, 2025

Bronfman’s Paramount bid could keep Shari Redstone involved...

August 27, 2024

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Troy Minerals Updates on Channel Sampling at Table Mountain High-Purity Silica Project, British Columbia, Canada

      October 17, 2025
    • McEwen to Acquire Canadian Gold in All-share Deal

      October 17, 2025
    • Crypto Market Update: Corporate Bitcoin Treasuries Jump to US$117 Billion

      October 17, 2025
    • AFDG via Butembo Acquisition Becomes First US Public Company in the Democratic Republic of the Congo (DRC)

      October 17, 2025
    • Tactical Resources Provides Rare Earths Business Update in Advance of Nasdaq Listing

      October 17, 2025
    Promotion Image

    banner ads

    Categories

    • Business (891)
    • Economy (829)
    • Investing (3,041)
    • Politics (737)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smarttradeinsights.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smarttradeinsights.com | All Rights Reserved